| General Information | |
|---|---|
| ZINC ID | ZINC000029125310 |
| Molecular Weight (Da) | 476 |
| SMILES | CCCCCn1nnc(-c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)c2C)n1 |
| Molecular Formula | C22Cl3N6 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 129.084 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 31 |
| LogP | 8.098 |
| Activity (Ki) in nM | 123.027 |
| Polar Surface Area (PSA) | 61.42 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.07811641 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.27 |
| Ilogp | 4.68 |
| Xlogp3 | 7.42 |
| Wlogp | 6.65 |
| Mlogp | 4.97 |
| Silicos-it log p | 5.79 |
| Consensus log p | 5.9 |
| Esol log s | -7.53 |
| Esol solubility (mg/ml) | 0.0000141 |
| Esol solubility (mol/l) | 2.97E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.54 |
| Ali solubility (mg/ml) | 0.00000137 |
| Ali solubility (mol/l) | 2.88E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.32 |
| Silicos-it solubility (mg/ml) | 0.00000022 |
| Silicos-it solubility (mol/l) | 4.80E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.93 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.6 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.213 |
| Logd | 5.104 |
| Logp | 6.665 |
| F (20%) | 0.004 |
| F (30%) | 0.007 |
| Mdck | - |
| Ppb | 98.67% |
| Vdss | 2.896 |
| Fu | 2.04% |
| Cyp1a2-inh | 0.296 |
| Cyp1a2-sub | 0.317 |
| Cyp2c19-inh | 0.896 |
| Cyp2c19-sub | 0.208 |
| Cl | 7.451 |
| T12 | 0.004 |
| H-ht | 0.115 |
| Dili | 0.989 |
| Roa | 0.354 |
| Fdamdd | 0.362 |
| Skinsen | 0.038 |
| Ec | 0.003 |
| Ei | 0.107 |
| Respiratory | 0.109 |
| Bcf | 3.926 |
| Igc50 | 5.284 |
| Lc50 | 7.083 |
| Lc50dm | 5.461 |
| Nr-ar | 0.005 |
| Nr-ar-lbd | 0.029 |
| Nr-ahr | 0.067 |
| Nr-aromatase | 0.9 |
| Nr-er | 0.902 |
| Nr-er-lbd | 0.754 |
| Nr-ppar-gamma | 0.111 |
| Sr-are | 0.937 |
| Sr-atad5 | 0.011 |
| Sr-hse | 0.009 |
| Sr-mmp | 0.938 |
| Sr-p53 | 0.508 |
| Vol | 440.091 |
| Dense | 1.077 |
| Flex | 0.318 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.281 |
| Synth | 2.57 |
| Fsp3 | 0.273 |
| Mce-18 | 23 |
| Natural product-likeness | -1.646 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |